At the symposium, Chairman Shi Yuan said that the global cell and gene therapy market showed a rapid growth trend, and compared the status quo and industrial production of cell therapy vector technology, pointing out that retroviral vectors have good cost advantages and market prospects. As the only one-stop service platform in China that has mastered the industrial-grade production process of retrovirus vectors, Shenzhen Cell Valley is an important strategic layout that conforms to industry trends and needs to better serve the whole country and even the world, realize innovative drugs to go to sea, and benefit patients around the world. Nathan McNally said that the UK has always been at the forefront of global innovation, relying on long-term government support, deep basic research, open innovation atmosphere and rich talent resources, and has become one of the best places in the world to develop, manufacture and commercialize cell and gene therapies. Lynn Huang said that the British government and top industry institutions have also supported many innovation programs to help the research and development of CGT products and clinical landing, enabling the incubation of innovative CGT innovative enterprises with great innovation strength.

This exchange visit has laid a good foundation for the follow-up cooperation and exchanges between the two sides, provided a good opportunity and platform for expanding business and boosting product technology, formed a joint force at home and abroad, and laid the foundation for achieving a new situation of development.